The science

Changing the way we treat skin

Tience® patented approach mimics the body’s natural functions by capturing the self-healing capabilities of human subcutaneous tissue. It’s tissue science, advanced through a groundbreaking technology where bioactive components are obtained from carefully selected tissue donors.

As a very active tissue with immense regenerative properties, subcutaneous tissue is the cornerstone of Tience. The balanced composition of bioactive components – including structural, protective, and cell-stimulating proteins, peptides, lipids, and antioxidants – accelerate skin regeneration, resulting in long-term improvement of skin quality and less visible skin defects.
Skin regeneration

Unique effects to skin functions

Tience® activates skin cells, which improves the overall functionality of the skin.

1.

Promotes renewal of the epidermis, which improves skin texture. Introduces lipids to the skin and supports their natural formation, maintaining a healthy skin barrier and improving moisture retention.

2.

Improves skin regeneration by stimulating the natural production of collagen and hyaluronic acid by skin cells.

3.

Activates microvascularization. Oxygen and nutrients are delivered to skin cells, which are essential for skin renewal.

Safety

Safety and long-term research are the foundation of Tience®

The safety of Tience® is a comprehensive entity that begins with the screening and testing of donated tissue. It is conducted in accordance with EU directives (2004/23/EC, 2006/17/EC, and 2006/86/EC), national legislation (Law 101/2001, Decree 594/2001, and Decree 1302/2007), and the regulation of Fimea (Finnish Medicines Agency) regarding the operation of tissue establishments (3/2014). In addition, Tience® undergoes more extensive testing than regulatory requirements to ensure product safety.

All Tience® products are manufactured in Finland. The safety of Tience® products is monitored at every stage of the production process, which takes place in a quality-controlled cleanroom. Before the product is delivered to healthcare professionals, it undergoes multi-stage quality assurance testing. This ensures that Tience® is sterile, suitable for injection, and does not cause allergic reactions in the body. Tience® consists only of effective biomolecules isolated from tissue and does not contain cells or additives.

Clinical safety research on Tience® has shown that it does not cause serious adverse effects, irritation reactions, or long-term adverse effects (Terveystalo Clinical Research, 2023). By June 2024,
more than 500 doses of Tience® treatments have been administered without any serious adverse reactions being reported.

Authorization and use

The regulatory authority overseeing and supervising the use of Tience® tissue products in Finland is Fimea, the Finnish Medicines Agency. In our operations, we comply with the European Union directives (2004/23/EC, 2012/39/EC, 2006/17/EC, 2015/565/EC, 2006/86/EC, 2015/566/EC) and national tissue legislation (regulations 101/2001, 1302/2007, and Fimea’s order 3/2014), under which Tience® treatments can be performed in healthcare facilities or other units whose mission is to use Tience® in human applications.

Additionally, Linio Biotech, as the manufacturer, requires that only nurses and doctors who have completed Tience® usage training may perform Tience® treatments in these facilities and units.

References

Key publications

Human adipose tissue extract induces angiogenesis and adipogenesis in vitro. Sarkanen JR, Kaila V, Mannerström B, Räty S, Kuokkanen H, Miettinen S, Ylikomi T. Tissue Eng Part A. 2012 Jan; 18 (1-2): 17-25.

Adipose tissue extract shows potential for wound Healing: in vitro proliferation and migration of cell types contributing to wound healing in the presence of adipose tissue preparation and platelet rich plasma. López JF, Sarkanen JR, Huttala O, Kaartinen IS, Kuokkanen HO, Ylikomi T. Cytotechnology. 2018 Aug; 70 (4): 1193-1204.

Cytokine-Rich Adipose Tissue Extract Production from Water-Assisted Lipoaspirate: Methodology for Clinical Use. Lopez J, Huttala O, Sarkanen JR, Kaartinen I, Kuokkanen H, Ylikomi T. Biores Open Access. 2016 Sep 1;5(1):269-78.

Adipose tissue as a source of growth factors to promote wound healing: a human study of skin graft donor sites. López JF, Mikkola A, Sarkanen JR, Kaartinen IS, Kuokkanen HO, Ylikomi T. Wound Care. 2022 Apr 2;31(4):282-92.

Mitä kauneuskirurgia on? Asko Salmi, Esa Saarinen. Duodecim 2017;133(22):2137-44

Scientific reports

Research report. Leppänen Minna, Kipar Anja, Mäkelä Tiina, Sarkanen Jertta-Riina, Ylikomi Timo. Pre-clinical safety evaluation of bioactive adipose tissue extract – long term repeated dose systemic toxicity study.

Clinical Investigation Report (Clinius CRO) 17.3.2023, Investigation site Terveystalo Oy Ruoholahti unit. Safety study evaluating the safety and tolerability of the Liponovo tissue product in healthy volunteers.

PhD Studies

Sarkanen Jertta-Riina, 2012: Engineering vascularized soft tissue

Huttala Outi, 2019: Human In Vitro Vascularization, Adipocytes and Vascularized Adipose Tissue: Three relevant models for studies of vascularization, adipocytes and their interaction.

Lopez Jenny, 2020: Adipose tissue extract induces wound healing.